Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy?

Yasutomo Nasu, Nobuyuki Kusaka, Haruki Kaku, Ryouji Arata, Yasuo Yamamoto, Tomoyasu Tsushima, Hiromi Kumon, Shin Ebara, Timothy C. Thompson

Research output: Contribution to journalArticle

Abstract

Gene therapy has been attracting much interest in the field of cancer therapy. Following the successful basic research outcome on gene therapy, clinical trials to evaluate the safety and efficacy of gene therapy have been initiated for many kinds of cancer. In this paper, the current status of prostate cancer gene therapy is reviewed focusing on the basic and clinical research outcome of adenovirus-mediated herpes simplex virus-thymidine kinase gene transduction and ganciclovir administration, so-called suicide gene therapy. Basic research on this suicide gene therapy for prostate cancer was conducted at the Baylor College of Medicine where the author was actively involved. A clinical phase 1 trail was also initiated at the Baylor College of Medicine to evaluate the safety and activity on prostate cancer. Future aspects of prostate cancer gene therapy are also discussed in this paper. The final goal of this innovative strategy is to develop and establish efficient treatment modalities for metastatic hormone-independent prostatic cancer. Many kinds of basic research are currently under way in an effort to realize the above goal.

Original languageEnglish
Pages (from-to)405-411
Number of pages7
JournalNishinihon Journal of Urology
Volume61
Issue number5
Publication statusPublished - May 1999

Fingerprint

Neoplasm Genes
Genetic Therapy
Prostatic Neoplasms
Suicide
Therapeutics
Medicine
Outcome Assessment (Health Care)
Safety
Ganciclovir
Thymidine Kinase
Simplexvirus
Research
Adenoviridae
Neoplasms
Clinical Trials
Hormones
Genes

Keywords

  • Ganciclovir
  • Gene therapy
  • GM-CSF
  • HSV-tk
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Nasu, Y., Kusaka, N., Kaku, H., Arata, R., Yamamoto, Y., Tsushima, T., ... Thompson, T. C. (1999). Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy? Nishinihon Journal of Urology, 61(5), 405-411.

Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy? / Nasu, Yasutomo; Kusaka, Nobuyuki; Kaku, Haruki; Arata, Ryouji; Yamamoto, Yasuo; Tsushima, Tomoyasu; Kumon, Hiromi; Ebara, Shin; Thompson, Timothy C.

In: Nishinihon Journal of Urology, Vol. 61, No. 5, 05.1999, p. 405-411.

Research output: Contribution to journalArticle

Nasu, Y, Kusaka, N, Kaku, H, Arata, R, Yamamoto, Y, Tsushima, T, Kumon, H, Ebara, S & Thompson, TC 1999, 'Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy?', Nishinihon Journal of Urology, vol. 61, no. 5, pp. 405-411.
Nasu, Yasutomo ; Kusaka, Nobuyuki ; Kaku, Haruki ; Arata, Ryouji ; Yamamoto, Yasuo ; Tsushima, Tomoyasu ; Kumon, Hiromi ; Ebara, Shin ; Thompson, Timothy C. / Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy?. In: Nishinihon Journal of Urology. 1999 ; Vol. 61, No. 5. pp. 405-411.
@article{7918b8b27bb048e592758ce27f30dd13,
title = "Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy?",
abstract = "Gene therapy has been attracting much interest in the field of cancer therapy. Following the successful basic research outcome on gene therapy, clinical trials to evaluate the safety and efficacy of gene therapy have been initiated for many kinds of cancer. In this paper, the current status of prostate cancer gene therapy is reviewed focusing on the basic and clinical research outcome of adenovirus-mediated herpes simplex virus-thymidine kinase gene transduction and ganciclovir administration, so-called suicide gene therapy. Basic research on this suicide gene therapy for prostate cancer was conducted at the Baylor College of Medicine where the author was actively involved. A clinical phase 1 trail was also initiated at the Baylor College of Medicine to evaluate the safety and activity on prostate cancer. Future aspects of prostate cancer gene therapy are also discussed in this paper. The final goal of this innovative strategy is to develop and establish efficient treatment modalities for metastatic hormone-independent prostatic cancer. Many kinds of basic research are currently under way in an effort to realize the above goal.",
keywords = "Ganciclovir, Gene therapy, GM-CSF, HSV-tk, Prostate cancer",
author = "Yasutomo Nasu and Nobuyuki Kusaka and Haruki Kaku and Ryouji Arata and Yasuo Yamamoto and Tomoyasu Tsushima and Hiromi Kumon and Shin Ebara and Thompson, {Timothy C.}",
year = "1999",
month = "5",
language = "English",
volume = "61",
pages = "405--411",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "5",

}

TY - JOUR

T1 - Current status and future aspects of prostate cancer gene therapy - Will it be a revolutionary therapy?

AU - Nasu, Yasutomo

AU - Kusaka, Nobuyuki

AU - Kaku, Haruki

AU - Arata, Ryouji

AU - Yamamoto, Yasuo

AU - Tsushima, Tomoyasu

AU - Kumon, Hiromi

AU - Ebara, Shin

AU - Thompson, Timothy C.

PY - 1999/5

Y1 - 1999/5

N2 - Gene therapy has been attracting much interest in the field of cancer therapy. Following the successful basic research outcome on gene therapy, clinical trials to evaluate the safety and efficacy of gene therapy have been initiated for many kinds of cancer. In this paper, the current status of prostate cancer gene therapy is reviewed focusing on the basic and clinical research outcome of adenovirus-mediated herpes simplex virus-thymidine kinase gene transduction and ganciclovir administration, so-called suicide gene therapy. Basic research on this suicide gene therapy for prostate cancer was conducted at the Baylor College of Medicine where the author was actively involved. A clinical phase 1 trail was also initiated at the Baylor College of Medicine to evaluate the safety and activity on prostate cancer. Future aspects of prostate cancer gene therapy are also discussed in this paper. The final goal of this innovative strategy is to develop and establish efficient treatment modalities for metastatic hormone-independent prostatic cancer. Many kinds of basic research are currently under way in an effort to realize the above goal.

AB - Gene therapy has been attracting much interest in the field of cancer therapy. Following the successful basic research outcome on gene therapy, clinical trials to evaluate the safety and efficacy of gene therapy have been initiated for many kinds of cancer. In this paper, the current status of prostate cancer gene therapy is reviewed focusing on the basic and clinical research outcome of adenovirus-mediated herpes simplex virus-thymidine kinase gene transduction and ganciclovir administration, so-called suicide gene therapy. Basic research on this suicide gene therapy for prostate cancer was conducted at the Baylor College of Medicine where the author was actively involved. A clinical phase 1 trail was also initiated at the Baylor College of Medicine to evaluate the safety and activity on prostate cancer. Future aspects of prostate cancer gene therapy are also discussed in this paper. The final goal of this innovative strategy is to develop and establish efficient treatment modalities for metastatic hormone-independent prostatic cancer. Many kinds of basic research are currently under way in an effort to realize the above goal.

KW - Ganciclovir

KW - Gene therapy

KW - GM-CSF

KW - HSV-tk

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0033068032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033068032&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 405

EP - 411

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 5

ER -